ERBB2 and breast cancer: A comprehensive proteomic analysis employing reverse-phase protein array (RPPA) technology on 289 breast cancer samples demonstrated higher ASCT2 and SHMT2 protein expression in aggressive subtypes, including HER2-positive and TNBC, compared to luminal subtypes [178].